公开(公告)号：EP2523952A1

公开(公告)日：2012-11-21

申请号：EP11702802.7

申请日：2011-01-12

申请人： AB Science

发明人： MOUSSY, Alain ,  BENJAHAD, Abdellah ,  MARTIN, Jason ,  CHEVENIER, Emmanuel ,  PEZ, Didier ,  SANDRINELLI, Franck ,  PICOUL, Willy

IPC分类号： C07D413/12 ,  C07D413/14 ,  C07D417/14 ,  A61K31/443 ,  A61K31/444 ,  A61K31/4436 ,  A61P35/00 ,  A61P37/00

CPC分类号： C07D413/14 ,  C07D413/12 ,  C07D417/14

摘要： The present invention is concerned with substituted azole derivatives that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant proteine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. In particular, several of these compounds are potent and selective Flt-3 inhibitors or/and syk inhibitors.

公开(公告)号：EP3253749A1

公开(公告)日：2017-12-13

申请号：EP16703138.4

申请日：2016-02-05

申请人： AB Science

发明人： MOUSSY, Alain ,  BENJAHAD, Abdellah ,  PEZ, Didier ,  SANDRINELLI, Franck ,  MARTIN, Jason ,  PICOUL, Willy ,  CHEVENIER, Emmanuel

IPC分类号： C07D413/14 ,  C07D413/10 ,  C07D417/10 ,  A61K31/439 ,  A61K31/4155 ,  A61K31/4178 ,  A61K31/5377 ,  A61K31/496 ,  A61K31/4196 ,  A61K31/4192 ,  A61K31/427 ,  A61P35/00 ,  C07D417/14

CPC分类号： C07D413/10 ,  A61K31/422 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/5377 ,  C07D413/14 ,  C07D417/10 ,  C07D417/14

摘要： The present invention relates to compounds of general formula (I). wherein A represents an optionally substituted heterocyclyl group, B represents an aryl or heteroaryl group and wherein X, R1, R2, R3, R4 and R5 are as defined in the description. Compounds of formula (I) are useful to destroy, inhibit, or prevent the growth or spread of cells, especially malignant cells, into surrounding tissues implicated in a variety of human and animal diseases

公开(公告)号：EP2736904B1

公开(公告)日：2016-03-16

申请号：EP12741307.8

申请日：2012-07-24

申请人： AB Science

发明人： BENJAHAD, Abdellah ,  MOUSSY, Alain ,  CHEVENIER, Emmanuel ,  PICOUL, Willy ,  LERMET, Anne ,  PEZ, Didier ,  MARTIN, Jason ,  SANDRINELLI, Franck

IPC分类号： C07D413/10 ,  C07D413/14 ,  C07D417/10 ,  C07D417/14 ,  A61P35/00 ,  A61K31/422 ,  A61K31/427

CPC分类号： A61K31/422 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  C07D413/10 ,  C07D413/14 ,  C07D417/10 ,  C07D417/14

公开(公告)号：EP2523952B1

公开(公告)日：2015-03-04

申请号：EP11702802.7

申请日：2011-01-12

申请人： AB Science

发明人： MOUSSY, Alain ,  BENJAHAD, Abdellah ,  MARTIN, Jason ,  CHEVENIER, Emmanuel ,  PEZ, Didier ,  SANDRINELLI, Franck ,  PICOUL, Willy

IPC分类号： C07D413/12 ,  C07D413/14 ,  C07D417/14 ,  A61K31/443 ,  A61K31/444 ,  A61K31/4436 ,  A61P35/00 ,  A61P37/00

CPC分类号： C07D413/14 ,  C07D413/12 ,  C07D417/14

公开(公告)号：EP3350176A1

公开(公告)日：2018-07-25

申请号：EP16769948.7

申请日：2016-09-16

申请人： AB Science

发明人： MOUSSY, Alain ,  BENJAHAD, Abdellah ,  PEZ, Didier ,  SCHALON, Claire ,  SANDRINELLI, Franck ,  MARTIN, Jason ,  PICOUL, Willy ,  CHEVENIER, Emmanuel

IPC分类号： C07D413/14 ,  A61K31/506 ,  A61P35/00 ,  A61P37/00

CPC分类号： C07D413/14

摘要： The present invention is concerned with substituted oxazole derivatives that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant protein kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, autoimmune, allergic, hematological, inflammatory and degenerative disorders. In particular, the compounds of the invention are Syk inhibitors. The invention also relates to a process for manufacturing the compounds of the invention.

公开(公告)号：EP3144307A1

公开(公告)日：2017-03-22

申请号：EP15185910.5

申请日：2015-09-18

申请人： AB Science

发明人： MOUSSY, Alain ,  BENJAHAD, Abdellah ,  PEZ, Didier ,  SCHALON, Claire ,  SANDRINELLI, Franck ,  MARTIN, Jason ,  PICOUL, Willy ,  CHEVENIER, Emmanuel

IPC分类号： C07D413/14 ,  A61K31/506 ,  A61P35/00 ,  A61P37/00

CPC分类号： C07D413/14

摘要： The present invention is concerned with substituted oxazole derivatives that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant protein kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, autoimmune, allergic, hematological, inflammatory and degenerative disorders. In particular, the compounds of the invention are Syk inhibitors. The invention also relates to a process for manufacturing the compounds of the invention.

摘要翻译： 本发明涉及选择性调节，调节和/或抑制由涉及各种人和动物疾病如细胞增殖，代谢，自身免疫，过敏的某些天然和/或突变蛋白激酶介导的信号转导的取代的恶唑衍生物 ，血液学，炎症和退行性疾病。 特别地，本发明的化合物是Syk抑制剂。 本发明还涉及制备本发明化合物的方法。

公开(公告)号：EP3122744A1

公开(公告)日：2017-02-01

申请号：EP15711211.1

申请日：2015-03-23

申请人： AB Science

发明人： BENJAHAD, Abdellah ,  MARTIN, Jason ,  SCHALON, Claire ,  PEZ, Didier ,  CHEVENIER, Emmanuel ,  SANDRINELLI, Franck ,  PICOUL, Willy ,  MOUSSY, Alain

IPC分类号： C07D413/14 ,  C07D417/14 ,  A61K31/499 ,  A61P35/00

CPC分类号： C07D413/14 ,  A61K31/506 ,  A61K31/5377 ,  C07D417/14

摘要： The present invention is concerned with substituted oxazole derivatives that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant protein kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, autoimmune, allergic, and degenerative disorders. In particular, the presently disclosed compounds are Syk inhibitors.

摘要翻译： 本发明涉及选择性调节，调节和/或抑制由涉及各种人和动物疾病如细胞增殖，代谢，自身免疫的某些天然和/或突变蛋白激酶介导的信号转导的二氮杂螺环烷酮取代的恶唑衍生物 ，过敏性和退行性疾病。 特别地，目前公开的化合物是Syk抑制剂。

公开(公告)号：EP3010906A1

公开(公告)日：2016-04-27

申请号：EP14732550.0

申请日：2014-06-20

申请人： AB Science

发明人： MOUSSY, Alain ,  BENJAHAD, Abdellah ,  SCHALON, Claire ,  PEZ, Didier ,  CHEVENIER, Emmanuel ,  SANDRINELLI, Franck ,  MARTIN, Jason ,  PICOUL, Willy

IPC分类号： C07D401/14 ,  C07D413/14 ,  A61K31/427 ,  A61K31/4406 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  C07D417/12 ,  C07D417/14 ,  A61P35/00 ,  A61P37/00 ,  A61P17/00 ,  A61P29/00 ,  A61P25/00

CPC分类号： C07D417/14 ,  A61K8/49 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  A61Q19/00 ,  C07D401/14 ,  C07D413/14 ,  C07D417/12

摘要： Disclosed are compounds of formula I or pharmaceutically acceptable salts thereof: Wherein n, R1, R2, R3, R4, R5, A, Q and X are as defined in the description. These compounds selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant protein kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. More particularly, these compounds are potent and selective native and/or mutant c-kit inhibitors.

摘要翻译： 公开了式I化合物或其药学上可接受的盐：其中n，R1，R2，R3，R4，R5，A，Q和X如说明书中所定义。 这些化合物选择性调节，调节和/或抑制由涉及各种人和动物疾病如细胞增殖，代谢，过敏和退行性疾病的某些天然和/或突变蛋白激酶介导的信号转导。 更具体地说，这些化合物是有效和选择性的天然和/或突变c-kit抑制剂。

公开(公告)号：EP3010906B1

公开(公告)日：2019-06-12

申请号：EP14732550.0

申请日：2014-06-20

申请人： AB Science

发明人： MOUSSY, Alain ,  BENJAHAD, Abdellah ,  SCHALON, Claire ,  PEZ, Didier ,  CHEVENIER, Emmanuel ,  SANDRINELLI, Franck ,  MARTIN, Jason ,  PICOUL, Willy

IPC分类号： C07D401/14 ,  C07D413/14 ,  A61K31/427 ,  A61K31/4406 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  C07D417/12 ,  C07D417/14 ,  A61P35/00 ,  A61P37/00 ,  A61P17/00 ,  A61P29/00 ,  A61P25/00

公开(公告)号：EP2736904A1

公开(公告)日：2014-06-04

申请号：EP12741307.8

申请日：2012-07-24

申请人： AB Science

发明人： BENJAHAD, Abdellah ,  MOUSSY, Alain ,  CHEVENIER, Emmanuel ,  PICOUL, Willy ,  LERMET, Anne ,  PEZ, Didier ,  MARTIN, Jason ,  SANDRINELLI, Franck

IPC分类号： C07D413/10 ,  C07D413/14 ,  C07D417/10 ,  C07D417/14 ,  A61P35/00 ,  A61K31/422 ,  A61K31/427

CPC分类号： A61K31/422 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  C07D413/10 ,  C07D413/14 ,  C07D417/10 ,  C07D417/14

摘要： The present invention relates to compounds of formula I or pharmaceutically acceptable salts thereof: wherein R
1 , R
2 , R
3 , A, Q, W and X are as defined in the description. These compounds selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant proteine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. More particularly, these compounds are potent and selective native and/or mutant c-kit inhibitors.